MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/85/0.1/20.09.24

MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/85/0.1/20.09.24 Share Price

DE000ME1FUL1

Real-time Bid/Ask 10:50:30 26/06/2024 pm IST
0.136 ^EUR / 0.145 ^EUR	-2.08%

Current month	+8.27%
1 month	-13.25%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/85/0.1/20.09.24

Latest news about ASTRAZENECA PLC

Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology	30/11	PR
New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy	14/23/14	PR
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research	27/22/27	PR
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer	14/22/14	PR

More news

Quotes 5-day view

Date	Price	Change
26/24/26	0.133	-7.64%
25/24/25	0.144	+2.86%
24/24/24	0.14	+2.19%
21/24/21	0.137	+7.03%
20/24/20	0.128	+7.56%

Delayed Quote Börse Stuttgart

Last update June 26, 2024 at 09:05 pm IST

More quotes

Static data

Product type	Warrant Plain-Vanilla
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	Morgan Stanley
WKN	ME1FUL
ISIN	DE000ME1FUL1
Date issued	03/10/2023
Strike	85 $
Maturity	20/09/2024 (86 Days)
Parity	10 : 1
Emission price	0.21 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.214 €
Lowest since issue	0.011 €
Spread	0.009 €
Spread %	6.12%

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: AstraZeneca PLC

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

159 USD

Average target price

174.4 USD

Spread / Average Target

+9.66%

Consensus